My ePortfolio Register   

ESMO 2017 /
Durvalumab in novel combinations for head and neck cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 525
Rating:

Dr Ezra Cohen - UC San Diego Health, San Diego, USA

Dr Cohen speaks with ecancer at the ESMO 2017 Congress in Madrid about the SCORES study assessing safety, tolerability, and preliminary anti-tumour activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck. 

He discusses how, of the two molecules targeting CXCR2 and STAT3 pathways, the influence of STAT3 on myeloid cells in the tumour microenvironment leads to significant response with a manageable toxicity profile.

Dr Cohen also spoke with ecancer about the KEYNOTE 40 trial of pembrolizumab in relapsed HNSCC, here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence